Regional Heterogeneity of the Results of Glucagon-Like Peptide 1 Receptor Agonist Trials in Type 2 Diabetes: A Reanalysis of Individual Participant Data.

Ariane JullienClément Jambon-BarbaraJean-Luc CracowskiBrian L ClaggettAnne-Laure BorelCharles KhouriMatthieu Roustit

Published in: Diabetes care (2024)

This study does not suggest any regional heterogeneity of GLP-1RA efficacy in MACE. However, a higher baseline risk and lower development status were associated with a greater benefit of these drugs.

Keyphrases

type diabetes
single cell
rheumatoid arthritis
cardiovascular disease
electronic health record
big data
glycemic control
metabolic syndrome
disease activity
ankylosing spondylitis
machine learning
artificial intelligence
deep learning
idiopathic pulmonary fibrosis